AstraZeneca Vaccine 79% Effective Preventing Symptomatic Disease and 100% Against Severe Disease

The findings of a large U.S. trial indicate that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization. 

The safety and efficacy analysis of the AstraZeneca vaccine, published Monday, was based on 32,449 participants across 88 trial centers in the U.S., Peru and Chile. Data from the large-scale trial study reaffirms that the vaccine is highly effective and safe. 

By comparison, Moderna’s vaccine was found to be more than 94% effective in preventing COVID-19 and Pfizer-BioNTech’s vaccine was found to be 95% effective. 

AstraZeneca said it will continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drug Administration for emergency use authorization in the following weeks. 

The results came shortly after several countries temporarily suspended the use of the AstraZeneca shot amid reports of blood clots in some vaccinated people. Health experts heavily criticized the temporary suspension, citing a lack of data, while other analysts expressed concern about the impact on vaccine uptake as the virus continued to spread. 

Germany, France, Italy and Spain have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects found the shot was safe and effective. 

The World Health Organization and the International Society on Thrombosis and Hemostasis have recommended that countries continue to use the Oxford-AstraZeneca vaccine. 

Dr. Peter Hotez, dean for the National School for Tropical Medicine at the Baylor College of Medicine, told CNN, “This is one of our workhorse vaccines that we’re expecting for Africa and Latin America. So this is good news also because its reaffirming for the vaccines used for global health as well.”

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.